Rakuten Medical Releases New, Post-hoc Analysis of Safety, Pharmacokinetic (PK), Immunogenicity and Biomarker Data from its Phase 1 & 1/2a Clinical Trials
Font : A-A+
- Two posters were presented during the European Society for Medical Oncology (ESMO) Congress 2019 on its RM-1929 photoimmunotherapy (PIT) treatment in patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC)
Post your Comments
Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer